Phone: +385 1 8886300

Email: fidelta@glpg.com

Patents

Fidelta's scientists are listed as co-inventors on many patent applications.

2011

  • New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases
    WO2011131749

2010

  • 3'-N-substituted 9-deoxo-9a-methyl-9a-aza-homoerythromycin having antimalarial activity
    WO2010086351
  • 9-Deoxo- 9a-methyl- 9a- aza- 9a-homoerythromycin a derivatives for the treatment of neutrophil dominated inflammatory diseases
    WO2010086350
  • Anti-inflammatory macrolide
    WO2010086349
  • Tricyclic azabicyclo [4.1.0] heptane derivatives as inhibitors of serotonin, dopamine and norepinephrine re-uptake
    WO2010146025

2009

  • 2'-O, 3' -N-bridged macrolides
    WO2009130189
  • 9-Deoxo-9a-methyl-9a-aza-9a-homoerythromycin a derivatives and their use for the treatment of malaria
    WO2009016142

2007

  • 9a-Substituted azalides for the treatment of malaria
    WO2007125414
  • Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract
    WO2007093840

2006

  • 4" Amino linked macrolides useful for the treatment of microbial infections
    WO2006120545
  • 9a-Carbamoil-γ-aminopropyl- and 9a-thiocarbamoyl-γ-aminopropyl-azalides with antimalarial activity
    WO2006075256
  • 9a-carbamoyl and thiocarbamoyl azalides with anti-inflammatory activity
    WO2006097849
  • 9a-Carbamoyl and thiocarbamoyl azalides with antimalarial activity
    WO2006087642
  • Anti-inflammatory conjugates of macrolides and coumarins
    WO2006092739
  • Anti-inflammatory macrolide conjugates
    WO2006075255
  • Bis-(coumarin) compounds with anti-inflammatory activity
    WO2006111858
  • Conjugates with anti-inflammatory activity
    WO2006046123
  • Decladinosyl macrolides with anti-inflammatory activity
    WO2006077501
  • Ether linked macrolides useful for the treatment of microbial infections
    WO2006120541
  • Macrolide compounds containing biotin and photo-affinity group for macrolide target identification
    WO2006106440
  • Macrolides with anti-inflammatory activity
    WO2006087644
  • Macrolone compounds
    WO2006050943
  • Macrolones
    WO2007054296
  • Macrolones - amino substituted quinolones
    WO2006050942
  • Monoamine reuptake inhibitors for treatment of cns diseases and disorders
    WO2006109190
  • Novel antimalarial 9a-carbamoyl-aminoalkyl and 9a-thiocarbamoyl-aminoalkyl azalides
    WO2006085228
  • Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract
    WO2006018698

2005

  • Carbamate linked macrolides useful for the treatment of microbial infections
    WO2005108413
  • Ester linked macrolides useful for the treatment of microbial infections
    WO2005108412
  • Furochromen derivative with antiinflamatora effect
    WO2005095411
  • Preparation of 1-aza-2-oxa-dibenzo[e,h]azulenes and their use for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
    WO2005049623
  • Solid state forms of (-)-(1R,2S)-2-amino-4-methylene-cyclopentanecarboxylic acid
    WO2005100302
  • Substituted furochromene compounds of antiinflammatory action
    WO2005010006
  • Supstituted furochromene compounds, their preparation and antiinflammatory activity
    WO2005010007
  • Use of 1,2-diaza-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
    WO2005049015
  • Use of 1,3-diaza-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
    WO2005049016
  • Use of 1-aza-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
    WO2005049011
  • Use of 1-oxa-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
    WO2005049010
  • Use of 1-thia-3-aza-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorder
    WO2005049020
  • Use of 2-thiadibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
    WO2005041856
  • Use of 3-aza-1-oxa-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
    WO2005049036
  • Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
    WO2005072728

2004

  • Derivatives of 1-thiadibenzoazulenes and their biological activity
    WO2004078763
  • Macrolide conjugates with antiinflammatory activity
    WO2004094449
  • Macrolides substituted at the 4"-position
    WO2004101585
  • New 3-decladinosyl 9a-N-carbamoyl and 9a-N-thiocarbamoyl derivatives of 9-deoxo-9-dihydro-9a-aza-9a homoeritromycin A
    WO2004101591
  • New 3-decladinosyl derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromicin A 9a,11-cyclic carbamates
    WO2004029067
  • New compounds, compositions and methods for treatment of inflammatory diseases and conditions
    WO2004005310
  • Novel 14 and 15 membered ring compounds
    WO2004101588
  • Novel 14 and 15 membered-ring compounds
    WO2004101587
  • Novel 14 and 15 membered-ring compounds
    WO2004101590
  • Novel 14 and 15 membered-ring compounds
    WO2004101586
  • Novel compounds, compositions as prodrug carriers for steroid/nonsteroid anti-inflammatory, antineoplastic and antiviral active molecules
    WO2004005313
  • Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
    WO2004005309
  • N''-substituted 9a-N-(N'-carbamoyl-γ-aminopropyl), 9a-N-(N'-thiocarbamoyl-γ-aminopropyl), 9a-N-[N'-(β-cyanoethyl)-N'-carbamoyl-γ-aminopropyl] and 9a-N-[N'-(β-cyanoethyl)-N'-thiocarbamoyl-γ-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A
    WO2004052904
  • Substituted 9a-N-[N’-(benzenesulfonyl)carbamoyl-γ-aminopropyl] and 9a-N-[N'-(β-cyanoethyl)-n'-(benzenesulfonyl)carbamoyl-γ-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A
    WO2004043984
  • Substituted 9a-N-{N'-[4-(sulfonyl)phenylcarbamoyl]} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A
    WO2004043985

2003

  • 1- or 3-Thia benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
    WO03084961
  • 1,2-Diaza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
    WO03099822
  • 1,3-Diaza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
    WO03099823
  • 1-Aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
    WO03097648
  • 1-Oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
    WO03084964
  • 1-Oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
    WO03097649
  • 1-Thia-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
    WO03099827
  • 2-Tia-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
    WO03084962
  • Macrolides
    WO03042228

2002

  • 9a-N-[N’-(phenylsulfonyl)carbamoyl]-derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and of 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A
    WO02068438
  • Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
    WO02055531
  • Macrolides
    WO0232917

2001

  • Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
    WO0187890

2000

  • Halo derivatives of 9-deoxo-9a-aza-9a-homerythromycin A
    WO00066603
  • Novel 8a- and 9a-15-membered lactams
    WO00063223
© 2015 All Rights Reserved - Fidelta Ltd.